Submitted:
08 February 2023
Posted:
09 February 2023
You are already at the latest version
Abstract
Keywords:
1. Introduction
2. Materials and Methods
2.1. Sample and Procedure
2.2. Measures
2.2.1. Substance Use and Motivational Factors
2.2.2. Anxiety & Depression
2.2.3. Perceived Stress
2.2.4. Insomnia Symptoms
2.3. Statistical analysis
3. Results
3.1. Prevalence
3.2. Motivating factors for illicit substance use
3.3. Relationships between psychiatric symptoms, illicit substance use and motivating factors
3.4. Substance type as predictors of anxiety, depression, stress, and insomnia
4. Discussion
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Holdaway, A. S.; Luebbe, A. M.; Becker, S. P. Rumination in relation to suicide risk, ideation, and attempts: Exacerbation by poor sleep quality? Journal of Affective Disorders 2018, 236, 6–13.
- Akram, U.; Ypsilanti, A.; Gardani, M.; Irvine, K.; Allen, S.; Akram, A.; Drabble, J.; Bickle, E.; Kaye, L.; Lipinski, D.; Matuszyk, E.; Sarlak, H.; Steedman, E.; Lazuras, L. Prevalence and psychiatric correlates of suicidal ideation in UK university students. Journal of Affective Disorders 2020, 272, 191–197. [CrossRef]
- Akram, U.; Akram, A.; Gardani, M.; Ypsilanti, A.; McCarty, K.; Allen, S.; Lazuras, L. The relationship between depression and insomnia symptoms amongst a sample of UK university students. Sleep Medicine Research 2019, 10, 49–53. [CrossRef]
- Ibrahim, A. K.; Kelly, S. J.; Adams, C. E.; Glazebrook, C. A systematic review of studies of depression prevalence in university students. Journal of Psychiatric Research 2013, 47, 391–400. [CrossRef]
- Walters, K. S.; Bulmer, S. M.; Troiano, P. F.; Obiaka, U.; Bonhomme, R. Substance use, anxiety, and depressive symptoms among college students. Journal of Child & Adolescent Substance Abuse 2018, 27, 103–111.
- Helmer, S. M.; Mikolajczyk, R. T.; McAlaney, J.; Vriesacker, B.; Van Hal, G.; Akvardar, Y.; Guillen-Grima, F.; Salonna, F.; Stock, C.; Dempsey, R. C.; Bewick, B. M.; Zeeb, H. Illicit substance use among university students from seven European countries: A comparison of personal and perceived peer use and attitudes towards illicit substance use. Preventive Medicine 2014, 67, 204–209. [CrossRef]
- Holloway, K. R.; Bennett, T. H.; Parry, O.; Gorden, C. Characteristics and consequences of prescription drug misuse among university students in the United Kingdom. Journal of Substance Use 2013, 19, 156–163. [CrossRef]
- Schulenberg, J.; Johnston, L. Monitoring the future National Survey results on drug use, 1975-2019: Volume II, college students and adults ages 19-60. 2020.
- El Ansari, W.; Vallentin-Holbech, L.; Stock, C. Predictors of illicit drug use among university students in Northern Ireland, Wales and England. Global Journal of Health Science 2014, 7.
- Bennett, T. H.; Holloway, K. R. Drug misuse among university students in the UK: Implications for prevention. Substance Use & Misuse 2013, 49, 448–455. [CrossRef]
- Harrison, L. Substance misuse and social work qualifying training in the British Isles: A survey of CQSW courses. Addiction 1992, 87, 635–642. [CrossRef]
- Webb, E.; Ashton, C. H.; Kelly, P.; Kamali, F. Alcohol and drug use in UK university students. The Lancet 1996, 348, 922–925. [CrossRef]
- Bogowicz, P.; Ferguson, J.; Gilvarry, E.; Kamali, F.; Kaner, E.; Newbury-Birch, D. Alcohol and other substance use among medical and law students at a UK university: A cross-sectional questionnaire survey. Postgraduate Medical Journal 2017, 94, 131–136. [CrossRef]
- Newbury-Birch, D.; White, M.; Kamali, F. Factors influencing alcohol and illicit drug use amongst medical students. Drug and Alcohol Dependence 2000, 59, 125–130. [CrossRef]
- Underwood, B.; Fox, K. A survey of alcohol and drug use among UK based dental undergraduates. British Dental Journal2000, 189, 314–317.
- Newbury-Birch, D.; Lowry, R. J.; Kamali, F. The changing patterns of drinking, illicit drug use, stress, anxiety and depression in dental students in a UK dental school: A longitudinal study. British Dental Journal 2002, 192, 646–649.
- Steward, A.; Pickersgill, M. Developing expertise, customising sleep, enhancing study practices: Exploring the legitimisation of modafinil use within the accounts of UK undergraduate students. Drugs: Education, Prevention and Policy 2019, 26, 347–355. [CrossRef]
- Webb, E.; Ashton, H.; Kelly, P.; Kamali, F. Patterns of alcohol consumption, smoking and illicit drug use in British university students: Interfaculty Comparisons. Drug and Alcohol Dependence 1997, 47, 145–153. [CrossRef]
- Lai, H. M.; Cleary, M.; Sitharthan, T.; Hunt, G. E. Prevalence of comorbid substance use, anxiety and mood disorders in epidemiological surveys, 1990–2014: A systematic review and meta-analysis. Drug and Alcohol Dependence 2015, 154, 1–13. [CrossRef]
- Suerken, C. K.; Reboussin, B. A.; Egan, K. L.; Sutfin, E. L.; Wagoner, K. G.; Spangler, J.; Wolfson, M. Marijuana use trajectories and academic outcomes among college students. Drug and Alcohol Dependence 2016, 162, 137–145. [CrossRef]
- Statistics every writer should know https://www.robertniles.com/stats/ (accessed Feb 8, 2023).
- Clark, H. A coordinated approach to student drug use surveys in Canada. Contemporary Drug Problems 2009, 36, 409–425. [CrossRef]
- Geramian, N.; Gharaat, L.; Taheri, S.; Mohebpour, F.; Nahvizadeh, M.; Farajzadegan, Z.; Heidari, K. [PDF] Development of a questionnaire to assess drug abuse among high school students of Isfahan Province, Iran: An action research: Semantic scholar https://www.semanticscholar.org/paper/Development-of-a-Questionnaire-to-Assess-Drug-Abuse-Geramian-Gharaat/4c66411538e1f554bbbd8f729621262cfcc517eb (accessed Feb 8, 2023).
- Zigmond, A. S.; Snaith, R. P. Hospital anxiety and depression scale. PsycTESTS Dataset 1983.
- Cohen, S.; Kamarck, T.; Mermelstein, R. Perceived stress scale. PsycTESTS Dataset 1983.
- Espie, C. A.; Kyle, S. D.; Hames, P.; Gardani, M.; Fleming, L.; Cape, J. The sleep condition indicator: A clinical screening tool to evaluate insomnia disorder: BMJ Open 2014, 4.
- Taylor, D. J.; Bramoweth, A. D.; Grieser, E. A.; Tatum, J. I.; Roane, B. M. Epidemiology of insomnia in college students: Relationship with Mental Health, quality of life, and substance use difficulties. Behavior Therapy 2013, 44, 339–348. [CrossRef]
- Akvardar, Y.; Demiral, Y.; Ergor, G.; Ergor, A. Substance use among medical students and physicians in a medical school in Turkey. Social Psychiatry and Psychiatric Epidemiology 2004, 39. [CrossRef]
- Al-Sayed, A. A.; Al-Rashoudi, A. H.; Al-Eisa, A. A.; Addar, A. M.; Al-Hargan, A. H.; Al-Jerian, A. A.; Al-Omair, A. A.; Al-Sheddi, A. I.; Al-Nowaiser, H. I.; Al-Kathiri, O. A.; Al-Hassan, A. H. Sedative drug use among King Saud University Medical Students: A cross-sectional sampling study. Depression Research and Treatment 2014, 2014, 1–7. [CrossRef]
- Cockcroft, K.; Grasko, D.; Fridjhon, P. On counting sheep: The self-medication and coping strategies of university students suffering from primary insomnia. South African Journal of Higher Education 2008, 20. [CrossRef]
- Goodhines, P. A.; Gellis, L. A.; Kim, J.; Fucito, L. M.; Park, A. Self-medication for sleep in college students: Concurrent and prospective associations with sleep and alcohol behavior. Behavioral Sleep Medicine 2017, 17, 327–341. [CrossRef]
- Shehnaz, S. I.; Agarwal, A. K.; Khan, N. A systematic review of self-medication practices among adolescents. Journal f Adolescent Health 2014, 55, 467–483. [CrossRef]
- Lader, M. H. Limitations on the use of benzodiazepines in anxiety and insomnia: Are they justified? European Neuropsychopharmacology 1999, 9.
- Nutt, D. J. Overview of diagnosis and drug treatments of anxiety disorders. CNS Spectrums 2005, 10, 49–56. [CrossRef]
- Parks, K. A.; Levonyan-Radloff, K.; Przybyla, S. M.; Darrow, S.; Muraven, M.; Hequembourg, A. University student perceptions about the motives for and consequences of nonmedical use of Prescription Drugs (NMUPD). Journal of American College Health 2017, 65, 457–465. [CrossRef]
- Glodosky, N. C.; Cuttler, C. Motives matter: Cannabis use motives moderate the associations between stress and negative affect. Addictive Behaviors 2020, 102, 106188. [CrossRef]
- Ketcherside, A.; Filbey, F. M. Mediating processes between stress and problematic marijuana use. Addictive Behaviors2015, 45, 113–118. [CrossRef]
- Yurasek, A. M.; Miller, M. B.; Pritschmann, R. K.; Curtis, A. F.; McCrae, C. S. Negative mood as a mediator of the association between insomnia severity and marijuana problems in college students. Journal of Sleep Research 2020, 29. [CrossRef]
- Akram, U.; Allen, S.; Stevenson, J. C.; Lazarus, L.; Ypsilanti, A.; Ackroyd, M.; Chester, J.; Longden, J.; Peters, C.; Irvine, K. R. Self-disgust as a potential mechanism underlying the association between body image disturbance and suicidal thoughts and behaviours. Journal of Affective Disorders 2022, 297, 634–640. [CrossRef]
- Powell, P. A.; Overton, P. G.; Simpson, J. The revolting self: An interpretative phenomenological analysis of the experience of self-disgust in females with depressive symptoms. Journal of Clinical Psychology 2013, 70, 562–578. [CrossRef]
- Ypsilanti, A.; Lazuras, L.; Powell, P.; Overton, P. Self-disgust as a potential mechanism explaining the association between loneliness and Depression. Journal of Affective Disorders 2019, 243, 108–115. [CrossRef]
- Ypsilanti, A.; Lazuras, L.; Robson, A.; Akram, U. Anxiety and depression mediate the relationship between self-disgust and insomnia disorder. Sleep Health 2018, 4, 349–351. [CrossRef]
- Bowles, N.; Herzig, M.; Shea, S. Recent legalization of cannabis use: Effects on sleep, health, and Workplace Safety. Nature and Science of Sleep 2017, Volume 9, 249–251. [CrossRef]
- Nicholson, A. N.; Turner, C.; Stone, B. M.; Robson, P. J. Effect of Δ-9-tetrahydrocannabinol and cannabidiol on nocturnal sleep and early-morning behavior in young adults. Journal of Clinical Psychopharmacology 2004, 24, 305–313. [CrossRef]
- Lissoni, P.; Resentini, M.; Mauri, R.; Esposti, D.; Esposti, G.; Rossi, D.; Legname, G.; Fraschini, F. Effects of tetrahydrocannabinol on melatonin secretion in man. Hormone and Metabolic Research 1986, 18, 77–78. [CrossRef]
- Murillo-Rodriguez, E.; Blanco-Centurion, C.; Sanchez, C.; Daniele, P.; Shiromani, P. J. Anandamide enhances extracellular levels of adenosine and induces sleep: An in vivo microdialysis study. Sleep 2003, 26, 943–947. [CrossRef]
- Helmer, S. M.; Mikolajczyk, R. T.; McAlaney, J.; Vriesacker, B.; Van Hal, G.; Akvardar, Y.; Guillen-Grima, F.; Salonna, F.; Stock, C.; Dempsey, R. C.; Bewick, B. M.; Zeeb, H. Illicit substance use among university students from seven European countries: A comparison of personal and perceived peer use and attitudes towards illicit substance use. Preventive Medicine 2014, 67, 204–209. [CrossRef]
- Makhoul, M.; Yates, F.; Wolfson, S. A survey of substance use at a UK university: Prevalence of use and views of students. Journal of Substance Misuse 1998, 3, 119–124. [CrossRef]
- Kounenou, K. Exploration of the relationship among drug use & alcohol drinking, entertainment activities and self-esteem in Greek university students. Procedia - Social and Behavioral Sciences 2010, 2, 1906–1910. [CrossRef]
- Schaeffer, G. M.; Schuckit, M. A.; Morrissey, E. R. Correlation between two measures of self-esteem and drug use in a college sample. Psychological Reports 1976, 39, 915–919. [CrossRef]
- Swaim, R. C.; Oetting, E. R.; Edwards, R. W.; Beauvais, F. Links from emotional distress to adolescent drug use: A path model. Journal of Consulting and Clinical Psychology 1989, 57, 227–231.
- Thorley, C., 2017. Not by Degrees: Not by Degrees: Improving Student Mental Health in the UK's Universities. Institute for Public Policy Research, London.
- Mortier, P.; Auerbach, R. P.; Alonso, J.; Bantjes, J.; Benjet, C.; Cuijpers, P.; Ebert, D. D.; Green, J. G.; Hasking, P.; Nock, M. K.; O’Neill, S.; Pinder-Amaker, S.; Sampson, N. A.; Vilagut, G.; Zaslavsky, A. M.; Bruffaerts, R.; Kessler, R. C.; Boyes, M.; Kiekens, G.; Baumeister, H.; Kaehlke, F.; Berking, M.; Ramírez, A. A.; Borges, G.; Díaz, A. C.; Durán, M. S.; González, R. G.; Gutiérrez-García, R. A.; de la Torre, A. E.; Martinez Martínez, K. I.; Medina-Mora, M. E.; Zarazúa, H. M.; Tarango, G. P.; Zavala Berbena, M. A.; O’Neill, S.; Bjourson, T.; Lochner, C.; Roos, J.; Cur, H. B.; Taljaard, L.; Saal, W.; Stein, D.; Alayo, I.; Almenara, J.; Ballester, L.; Barbaglia, G.; Blasco, M. J.; Castellví, P.; Cebrià, A. I.; Echeburúa, E.; Gabilondo, A.; García-Forero, C.; Iruin, Á.; Lagares, C.; Miranda-Mendizábal, A.; Parès-Badell, O.; Pérez-Vázquez, M. T.; Piqueras, J. A.; Roca, M.; Rodríguez-Marín, J.; Gili, M.; Soto-Sanz, V.; Vives, M. Suicidal thoughts and behaviors among first-year college students: Results from the WMH-ICS project. Journal of the American Academy of Child & Adolescent Psychiatry 2018, 57. [CrossRef]
- O'Neill, S.; McLafferty, M.; Ennis, E.; Lapsley, C.; Bjourson, T.; Armour, C.; Murphy, S.; Bunting, B.; Murray, E. Socio-demographic, mental health and childhood adversity risk factors for self-harm and suicidal behaviour in college students in Northern Ireland. Journal of Affective Disorders 2018, 239, 58–65. [CrossRef]
- Renshaw, T. L.; Cohen, A. S. Life satisfaction as a distinguishing indicator of college student functioning: Further validation of the two-continua model of Mental Health. Social Indicators Research 2013, 117, 319–334. [CrossRef]
- Beiter, R.; Nash, R.; McCrady, M.; Rhoades, D.; Linscomb, M.; Clarahan, M.; Sammut, S. The prevalence and correlates of depression, anxiety, and stress in a sample of college students. Journal of Affective Disorders 2015, 173, 90–96.
- Otufowora, A.; Liu, Y.; Young, H.; Egan, K. L.; Varma, D. S.; Striley, C. W.; Cottler, L. B. Sex differences in willingness to participate in research based on study risk level among a community sample of African Americans in North Central florida. Journal of Immigrant and Minority Health 2020, 23, 19–25. [CrossRef]
| 1 | Provided points required for completion of a study module completion. |
| 2 | In the UK, cannabis remains an illegal class b substance. |
| Drug Type | Month (n) | Year (n) | Lifetime (n) |
|---|---|---|---|
| Cannabis | 25.8 % (138) | 46.3 % (249) | 58.7 % (316) |
| Cocaine | 13. 4% (72) | 25.7 % (138) | 31.2 % (168) |
| Amphetamine | 1.1 % (6) | 4.1 % (22) | 8.9 % (48) |
| Methamphetamine | 0.4 % (2) | 0.4 % (2) | 0.6 % (3) |
| Nootropic | 1.9 % (10) | 3.6 % (19) | 6.3 % (34) |
| Ketamine | 13.1 % (70) | 24.5 % (131) | 28.6 % (154) |
| Hallucinogenic | 3.9 % (21) | 9.5 % (51) | 13.3 % (72) |
| MDMA | 11.6 % (62) | 25.2 % (135) | 31.2 % (168) |
| Nitrous Oxide | 11.2 % (60) | 28.4 % (152) | 38.8 % (209) |
| Sedative Hypnotics | 1.7 % (9) | 5.6 % (30) | 9.2 % (50) |
| Heroin | 0.4 % (2) | 0.4 % (2) | 0.6 % (3) |
| All Other Opioids | 2.6 % (14) | 8.4 % (45) | 12.9 % (70) |
| Composite Score | 0.87 ± 1.52 (466) | 1.81 ± 2.69 (976) | 2.39 ± 2.63 (1295) |
| Measures | Mean ± Standard Deviation |
|---|---|
| Anxiety | 8.88 ± 4.63 |
| Depression | 5.50 ± 3.80 |
| Stress | 22.27 ± 6.96 |
| Insomnia | 17.80 ± 7.90 |
| Cited Reasons for Drug Use^ | |
| Curiosity | 1.84 ± 1.43 |
| Boredom | 6.11 ± 1.72 |
| Peer pressure | 5.03 ± 2.65 |
| Pleasure | 3.12 ± 1.77 |
| Low cost and availability | 6.79 ± 2.11 |
| Low self-confidence | 5.84 ± 2.06 |
| Self-medication | 6.93 ± 2.82 |
| Little knowledge concerning expected and unexpected side effects | 6.94 ± 1.77 |
| Parental or sibling addiction | 8.86 ± 1.89 |
| Provided by a peer | 3.55 ± 1.84 |
| Composite Substance Use | |||||||
|---|---|---|---|---|---|---|---|
| Influencing Factor | Anxiety | Depression | Stress | Insomnia | Past Month | Past Year | Lifetime |
| Curiosity | .04 | −.08 | −.01 | −.06 | −.05 | −.03 | .01 |
| Boredom | .05 | .03 | −.04 | −.07 | −.04 | −.10* | -.11* |
| Peer pressure | .08 | .05 | .11* | .14 | .21** | .29** | .29** |
| Pleasure | .10* | .09 | .03 | −.06 | −.17** | −.27** | -.24** |
| Low cost/availability | .12* | .16** | .15** | −.07 | −.17** | −.28** | -.23** |
| Low self-confidence | −.21** | −.13** | −.16** | .11* | .10* | .15** | .13** |
| Self-medication | −.32** | −.21** | −.23** | .21** | −.07 | −.09* | -.12* |
| Lack of knowledge | .09 | .05 | .07 | −.06 | .04 | .10* | .07 |
| Parental/sibling | .01 | −.02 | .01 | .01 | .05 | .13** | .09 |
| Provided by a peer | .19** | .14** | .15** | −.05 | .04 | .03 | .04 |
| Composite Substance Use | |||||||
| Lifetime | .18** | .16** | .15** | −.11** | − | − | - |
| Past Year | .13** | .16** | .12** | −.13** | − | − | - |
| Past Month | .12** | .17** | .09* | −.11** | − | − | - |
| Month | Year | Lifetime | |||||||
|---|---|---|---|---|---|---|---|---|---|
| β | t | P | β | t | P | β | t | P | |
| [A] Anxiety | R2 = .06 | R2 = .08 | R2 = .08 | ||||||
| Cannabis | .434 | .841 | .401 | .399 | .842 | .400 | .846 | .090 | .074 |
| Cocaine | −.196 | −.267 | .790 | −.129 | −.199 | .843 | .458 | .046 | .496 |
| Amphetamine | 6.914 | 2.796 | .005** | 2.028 | 1.817 | .070 | 1.397 | .085 | .112 |
| Methamphetamine | − | − | − | − | − | − | 6.684 | .108 | .062 |
| Nootropic | −2.014 | −1.180 | .239 | .556 | .474 | .635 | 2.046 | .108 | .025* |
| Ketamine | .655 | .829 | .407 | −.212 | −.311 | .756 | −.059 | −.006 | .925 |
| Hallucinogenic | −1.722 | −1.499 | .135 | −1.513 | −1.846 | .066 | −1.947 | −.143 | .013* |
| MDMA | −.397 | −.518 | .605 | .435 | .635 | .526 | .384 | .038 | .560 |
| Nitrous Oxide | .292 | .393 | .695 | −.738 | −1.330 | .184 | −.891 | −.094 | .102 |
| Sedative Hypnotics | 5.432 | 3.046 | .002** | 2.030 | 2.066 | .039* | 1.354 | .084 | .104 |
| Heroin | .613 | .150 | .881 | 5.069 | 1.489 | .137 | −3.311 | −.053 | .357 |
| All Other Opioids | .813 | .607 | .544 | 3.287 | 4.150 | .000** | 1.704 | .122 | .012* |
| [B] Depression | R2 = .08 | R2 = .08 | R2 = .09 | ||||||
| Cannabis | .883 | 2.116 | .035* | −.085 | −.219 | .827 | .419 | 1.087 | .278 |
| Cocaine | −.117 | −.197 | .844 | −.001 | −.001 | .999 | .425 | .774 | .439 |
| Amphetamine | 5.799 | 2.901 | .004** | 2.074 | 2.268 | .024* | 1.202 | 1.680 | .094 |
| Methamphetamine | − | − | − | − | − | − | 6.569 | 2.254 | .025* |
| Nootropic | −1.295 | −.939 | .348 | 1.040 | 1.082 | .280 | 1.436 | 1.940 | .053 |
| Ketamine | −.289 | −.452 | .651 | .703 | 1.258 | .209 | .336 | .653 | .514 |
| Hallucinogenic | −1.635 | −1.761 | .079 | −1.052 | −1.566 | .118 | −1.715 | −2.679 | .008** |
| MDMA | .576 | .928 | .354 | .442 | .786 | .432 | .566 | 1.054 | .292 |
| Nitrous Oxide | .186 | .311 | .756 | −.839 | −1.845 | .066 | −1.160 | −2.615 | .009** |
| Sedative Hypnotics | 3.545 | 2.459 | .014* | 1.726 | 2.143 | .033* | 1.351 | 1.994 | .047* |
| Heroin | 5.869 | 1.781 | .076 | 9.375 | 3.360 | .001** | 1.151 | .393 | .695 |
| All Other Opioids | .419 | .387 | .699 | .801 | 1.234 | .218 | .471 | .857 | .392 |
| [C] Stress | R2 = .04 | R2 = .06 | R2 = .05 | ||||||
| Cannabis | 1.669 | 2.124 | .034* | 1.618 | 2.238 | .026* | 1.551 | 2.151 | .032* |
| Cocaine | −.748 | −.668 | .504 | .134 | .135 | .892 | .693 | .675 | .500 |
| Amphetamine | 5.622 | 1.494 | .136 | 2.449 | 1.441 | .150 | 1.217 | .910 | .363 |
| Methamphetamine | − | − | − | − | − | − | .828 | .152 | .879 |
| Nootropic | 1.126 | .434 | .665 | 2.730 | 1.528 | .127 | 3.404 | 2.461 | .014* |
| Ketamine | −.759 | −.632 | .528 | −.579 | −.558 | .577 | .757 | .787 | .431 |
| Hallucinogenic | −3.805 | −2.177 | .030* | −3.194 | −2.557 | .011* | −3.018 | −2.522 | .012* |
| MDMA | .075 | .064 | .949 | 1.198 | 1.146 | .252 | .259 | .258 | .796 |
| Nitrous Oxide | 1.230 | 1.089 | .277 | −1.675 | −1.982 | .048* | −1.024 | −1.235 | .217 |
| Sedative Hypnotics | 4.899 | 1.806 | .072 | 1.651 | 1.103 | .271 | 1.459 | 1.152 | .250 |
| Heroin | −.342 | −.055 | .956 | 2.106 | .406 | .685 | −.824 | −.150 | .881 |
| All Other Opioids | 1.084 | .532 | .595 | 3.471 | 2.877 | .004** | .765 | .744 | .457 |
| [D] Insomnia | R2 = .05 | R2 = .05 | R2 = .07 | ||||||
| Cannabis | −2.065 | −2.339 | .020* | −1.872 | −2.269 | .024* | −1.641 | −2.027 | .043* |
| Cocaine | .064 | .051 | .960 | .178 | .157 | .875 | −1.321 | −1.146 | .252 |
| Amphetamine | −8.738 | −2.067 | .039* | −2.513 | −1.296 | .196 | −2.587 | −1.723 | .085 |
| Methamphetamine | − | − | − | − | − | − | −20.231 | −3.307 | .001** |
| Nootropic | 4.621 | 1.584 | .114 | −.749 | −.368 | .713 | −3.771 | −2.428 | .016** |
| Ketamine | −.926 | −.686 | .493 | −.418 | −.353 | .724 | −.109 | −.101 | .920 |
| Hallucinogenic | 4.366 | 2.223 | .027* | 2.559 | 1.796 | .073 | 3.751 | 2.792 | .005** |
| MDMA | −.286 | −.218 | .828 | −.575 | −.483 | .630 | −.876 | −.777 | .438 |
| Nitrous Oxide | .485 | .382 | .703 | 1.643 | 1.704 | .089 | 2.556 | 2.746 | .006** |
| Sedative Hypnotics | −8.929 | −2.929 | .004** | −3.938 | −2.306 | .022* | −1.077 | −.758 | .449 |
| Heroin | −1.241 | −.178 | .859 | −6.010 | −1.016 | .310 | 14.332 | 2.330 | .020* |
| All Other Opioids | −.791 | −.346 | .730 | −2.144 | −1.558 | .120 | −1.159 | −1.004 | .316 |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
